Trial Profile
A Trial of the Effect of Rosiglitazone as Add on to Metformin Therapy on Endothelial Function in Subjects With Type II DM
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms GATE
- 15 Mar 2010 Secondary endpoint 'Endothelial function' has not been met according to results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC 2010).
- 14 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC 2010).
- 26 Oct 2008 Actual patient number (40) added as reported by ClinicalTrials.gov.